Neuren Pharmaceuticals (ASX: NEU)

Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. www.neurenpharma.com

Neuren Pharmaceuticals ASX NEU FDA grants orphan drug designation Phelan-McDermid Pitt Hopkins syndrome

Neuren Pharma granted orphan drug status for treatment of Phelan-McDermid, Pitt Hopkins and Angelman syndromes

A drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopmental disorders has been granted orphan drug ...
Neuren Pharmaceuticals ASX NEU NNZ-2591 Pitt Hopkins Angelman syndrome model

Neuren’s NNZ-2591 drug candidate alleviates Pitt Hopkins and Angelman syndrome symptoms

Neuren Pharmaceuticals (ASX: NEU) has revealed positive pre-clinical results for its NNZ-2591 drug candidate in treating Pitt Hopkins and Angelm...
Neuren Pharmaceuticals ASX NEU ACADIA Pharma trofinetide Rett Syndrom licence US

Neuren Pharmaceuticals receives first payment in Rett drug licence deal

Neuren Pharmaceuticals (ASX: NEU) has received the first US$10 million payment under a recently announced licence deal with US-based ACADIA Phar...
Neuren Pharmaceuticals NEU Phase 3 FDA approval Rett syndrome

FDA greenlights Neuren Pharmaceuticals to kick-off next trial for Rett drug

Melbourne-based Neuren Pharmaceuticals (ASX: NEU) reported the US Food and Drug Administration has given the greenlight for the company to start...
Small Caps ASX Australian stock market
Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
Copyright 2020 Small Caps. All rights reserved.